The Joy Of Monopolies: Orphan Drug Price Increasing By Nearly 40% Each Year

from the no-surprise-there dept

A couple of years ago, Techdirt carried an article by Andy Kessler about the difference between entrepreneurs who create value, and those who lock it up. The former tend to drive prices down constantly, innovating all the while in order to make a profit; the latter, by contrast, typically enjoy monopolies that allow them to push up prices without offering anything more in return.

Here's another great example of the latter from The New York Times, which concerns so-called "orphan drugs" -- that is, those intended to treat more uncommon diseases, which are often overlooked by Big Pharma only interested in Big Markets and Big Profits. Here's what happened with a company called Jazz:

To get drug developers to focus on these relatively small pools of patients, the federal government offers inducements like a 50 percent research-and-development tax credit as well as a longer period of market exclusivity (seven years after Food and Drug Administration approval, rather than the typical five). These long monopolies often give orphan drug makers a free hand to raise prices.

That's precisely what Jazz has done, often multiple times each year, at an average annual rate of nearly 40 percent. Today, Xyrem costs more than $65,000 per year for the typical user.
Of course, the standard justification for such incredibly expensive drugs is that they are incredibly expensive to develop. Techdirt has debunked that notion in general, and The New York Times article does so again for this particular case:
Xyrem, which is a modification of a long-available compound, was inexpensive to develop, as new drugs go. Indeed, Jazz paid only $146 million for Orphan Medical [the company that did the original work on Xyrem and other orphan drugs], just a fraction of what it now earns each year from Xyrem alone. (The company contends that it has spent considerably on its development.)
So however laudable the aim of the 1983 Orphan Drug Act might have been, its effect can turn out to be just what you would expect from granting yet more government-backed monopolies: ever-higher prices for no additional benefit -- the very definition of a company locking up value, rather than creating it.

Follow me @glynmoody on Twitter or identi.ca, and on Google+

Filed Under: drugs, monopolies, orphan drugs, patents, pharmaceuticals
Companies: jazz


Reader Comments

Subscribe: RSS

View by: Time | Thread


  1. identicon
    Anonymous Coward, 29 Aug 2013 @ 6:10am

    any wonder why the drug cartels want to destroy companies making 'look alikes' at a fraction of the price or why the USG is doing whatever it takes to keep the monopolies alive (as long as the drug companies concerned are American, that it!)

Add Your Comment

Have a Techdirt Account? Sign in now. Want one? Register here



Subscribe to the Techdirt Daily newsletter




Comment Options:

  • Use markdown. Use plain text.
  • Remember name/email/url (set a cookie)

Follow Techdirt
Special Affiliate Offer

Advertisement
Report this ad  |  Hide Techdirt ads
Essential Reading
Techdirt Deals
Report this ad  |  Hide Techdirt ads
Techdirt Insider Chat
Advertisement
Report this ad  |  Hide Techdirt ads
Recent Stories
Advertisement
Report this ad  |  Hide Techdirt ads

This site, like most other sites on the web, uses cookies. For more information, see our privacy policy. Got it
Close

Email This

This feature is only available to registered users. Register or sign in to use it.